EudraCT Public website -NCAs page

<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN"> <html> <head> <title>EudraCT Public website -NCAs page</title> <meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /> <link href="css/eudractold.css" rel="stylesheet" type="text/css"/> <link href="css/eudract.css" rel="stylesheet" type="text/css"/>  <script language="JavaScript" type="text/javascript" src="Styles/common_functions.js"></script> <style type="text/css">  </style> </head> <body onload="javascript:showHideMsg()">  <table class="headerTableGlobal" width="100%" cellspacing="0" cellpadding="0"> <tr width="100%"> <td width="58%"align="left" id="rowTop1"><img src="images/eudractlefthead.png" width="400" height="36" alt="EudraCT"></td> <td width="42%" align="right" id="rowTop2" > </td> </tr>   <tr width="100%"> <td align="left" id="rowBottom1"> </td> <td align="right" id="rowBottom2" >Hosted on behalf of the European Commission<a href="http://ec.europa.eu/index_en.htm" title="European Commission" target="_blank"><img src="images/smalleuflag.gif" width="30" height="20" alt="EU"></a></td> </tr> </table>  <div id="Layer3" style="position: absolute; width: 211px; height: 115px; z-index: 3; top: 70px; left: 9px; visibility: visible;"> <table width="100%" border="0" cellpadding="1" cellspacing="0" > <tr> <td class="textBody"><a href="index.html">Home</a></td> </tr> <tr><td class="line"></td></tr> <tr> <td class="textBody"><a href="https://eudract.ema.europa.eu/results-web/" target="_blank">EudraCT tools & Login</a></td> </tr> <tr><td class="line"></td></tr> <tr> <td class="textBody"><a href="protocol.html">EudraCT step-by-step guide</a></td> </tr> <tr><td class="line"></td></tr> <tr> <td class="textBody"><a href="multimedia_tutorials.html">Tutorials on posting results</a></td> </tr> <tr><td class="line"></td></tr> <tr> <td class="textBody"><a href="training.html">User manual and training</a></td> </tr> <tr><td class="line"></td></tr> <tr> <td class="textBody"><a href="result.html">Supporting documents</a></td> </tr> <tr><td class="line"></td></tr> <tr> <td class="textBody"><a href="docs/guidance/EudraCT FAQ_for publication.pdf" target="_blank">Frequently asked questions</a></td> </tr> <tr><td class="line"></td></tr> <tr> <td class="textBody"><a href="nca_contacts.html">National competent authorities</a></td> </tr> <tr><td class="line"></td></tr> <tr> <td class="textBody"><a href="https://www.clinicaltrialsregister.eu/ctr-search/search/" target="_blank">EU Clinical Trials Register</a></td> </tr> <tr><td class="line"></td></tr> <tr> <td class="textBody"><a href="contact.html">Need Help? Contact us!</a></td> </tr> <![if ! IE 6]> <div> <tr> <td class="line"></td> </tr> </div> <![endif]> </table> </div> <table width="98%" border="0" cellspacing="3" cellpadding="6" class="data"> <table style="margin-left:228px; margin-right:145px;"> <tr> <td colspan="4" class="line"></td> <tr> <td colspan="5" bgcolor="#F3F3F3" class="textBody"><h1>National competent authorities (NCAs)</h1> </tr> <tr> <td colspan="5" bgcolor="#F3F3F3" class="textBody">As of 31 January 2025, all EU/EEA trials will need to be conducted under <a href="https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:32014R0536" target="_blank">Regulation (EU) 536/2014</a>. Any EU/EEA trial with a foreseen last patient last visit after this date is required to be <a href="https://euclinicaltrials.eu/guidance-and-q-as/#qas-transitioning" target="_blank">transitioned to the Clinical Trial Information System</a> as soon as possible. Sponsors of EU/EEA EudraCT trials (foreseen to be) completed/prematurely ended before 31 January 2025 need to submit an <a href="https://health.ec.europa.eu/document/download/c6106c25-4a19-4f53-b2dd-ad5e47b4f197_en?filename=declaration_end_trial_form.doc" target="_blank">End of Trial form</a> to the relevant NCA, or to use the available NCA tools (see below websites), in order to mark the trial accordingly. </tr> <tr> <td bgcolor="#F3F3F3" class="simpleLabelBold">Country <td bgcolor="#F3F3F3" class="simpleLabelBold">Department for Clinical Trials <td width="440" bgcolor="#F3F3F3" class="simpleLabelBold">Contact points for information on Clinical Trials <td bgcolor="#F3F3F3" class="simpleLabelBold">Logo <td width="2" bgcolor="#F3F3F3" class="textBody"></tr> <tr> <td width="97" bgcolor="#FFFFFF" class="textBody">Austria <td width="359" nowrap bgcolor="#FFFFFF" class="textBody"> <a href="http://www.basg.gv.at/en/basg-austrian-federal-office-for-safety-in-health-care/" target="_blank">BASG - Austrian Federal Office for Safety in Health Care</a> <a href="http://www.ages.at/en/startseite/" target="_blank">AGES - Austrian Medicines & Medical Devices Agency </a> <td nowrap bgcolor="#FFFFFF" class="textBody">Traisengasse 5 1200 Vienna Austria tel: 0043 (0)50555 36827 e-mail:<a href="mailto:clinicaltrials@ages.at">clinicaltrials@ages.at</a> website: <a href="http://www.basg.gv.at/en/medicines/prior-to-authorisation/clinical-trials/" target="_blank">http://www.basg.gv.at/en/medicines /</a><a href="http://www.basg.gv.at/en/medicines/prior-to-authorisation/clinical-trials/" target="_blank">prior-to-authorisation/clinical-trials/</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/austria.gif" alt="" width="46" height="51"> <img src="ncalogos/AGES.jpg" alt="" width="253" height="97"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Belgium <td bgcolor="#F3F3F3" class="textBody"><a href="http://www.fagg-afmps.be" target="_blank">FAMHP </a> <td bgcolor="#F3F3F3" class="textBody">Galileelaan - Avenue Galil茅e 5/03 1210 BRUXELLES T + 32 2 528 40 00 email: <A href="mailto:ct.rd@fagg-afmps.be">ct.rd@fagg-afmps.be</A> website: <a href="http://www.fagg-afmps.be " target="_blank">http://www.fagg-afmps.be </a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/belgian.jpg" alt="" width="200" height="74"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Bulgaria <td bgcolor="#FFFFFF" class="textBody"><a href="http://www.bda.bg/" target="_blank">Bulgarian Drug Agency </a> <td bgcolor="#FFFFFF" class="textBody">8, Damyan Gruev Str. 1303, Sofia, Bulgaria tel: + 359 2 8903555 fax:+ 359 2 8903434 e-mail: <a href="mailto:bda@bda.bg">bda@bda.bg</a> website: <a href="http://www.bda.bg/" target="_blank">http://www.bda.bg/</a> Department Clinical Trials tel: + 359 2 8903491 <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/bulgarian.jpg" alt="" width="113" height="102"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody"> Croatia <td bgcolor="#F3F3F3" class="textBody"><a href="https://zdravlje.gov.hr/" target="_blank">Ministry of Health </a> <td bgcolor="#F3F3F3" class="textBody">Ksaver 200a 10000 Zagreb Croatia tel: +385 1 46 07 555 fax: +385 1 46 77 076 e-mail: <a href="mailto:pisarnica@miz.hr">pisarnica@miz.hr</a> website: <a href="https://zdravlje.gov.hr/">https://zdravlje.gov.hr/</a> <a href="https://zdravlje.gov.hr/o-ministarstvu/djelokrug-1297/lijekovi-i-medicinski-proizvodi-1349/1349">https://zdravlje.gov.hr/o-ministarstvu/djelokrug-1297/lijekovi-i-medicinski-proizvodi-1349/1349</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/croatia.jpg" width="188" height="77" alt="Croatia"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Czech Republic <td bgcolor="#F3F3F3" class="textBody"><a href="http://www.sukl.cz/" target="_blank">State Institute for Drug Control </a> <td bgcolor="#F3F3F3" class="textBody">艩rob谩rova 48 100 41 Praha 10 tel: + 00 420272185817 fax: + 00 420272185816 e-mail: <a href="mailto:posta@sukl.cz">posta@sukl.cz</a> website: <a href="http://www.sukl.cz/" target="_blank">http://www.sukl.cz/</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/czech.jpg" alt="" width="151" height="65"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Denmark <td bgcolor="#FFFFFF" class="textBody"><a href="https://laegemiddelstyrelsen.dk/en/" target="_blank">Danish Medicines Agency</a><td bgcolor="#FFFFFF" class="textBody">NCA Clinical trial unit e-mail: <a href="mailto:kf@dkma.dk">kf@dkma.dk</a> NCA e-mail: <a href="mailto:dkma@dkma.dk">dkma@dkma.dk</a> Q&A: <a href="https://laegemiddelstyrelsen.dk/en/licensing/clinical-trials/clinical-trials-questions-and-answers/" target="_blank">http://laegemiddelstyrelsen.dk/en/licensing/clinical-trials/clinical-trials-questions-and-answers</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/denmark.gif" width="311" height="162" alt=""/> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Estonia <td bgcolor="#F3F3F3" class="textBody"><a href="http://www.ravimiamet.ee/" target="_blank">Republic of Estonia Agency of Medicines </a> <td bgcolor="#F3F3F3" class="textBody">email:<a href="mailto:trials@ravimiamet.ee ">trials@ravimiamet.ee </a> website: <a href="http://www.ravimiamet.ee/ ">http://www.ravimiamet.ee/ </a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/estonia.jpg" width="265" height="80"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Finland <td bgcolor="#FFFFFF" class="textBody"><a href="http://www.fimea.fi" target="_blank">Finnish Medicines Agency FIMEA</a> <td bgcolor="#FFFFFF" class="textBody">P.O.Box 55,  FI-00034 FIMEA, Finland tel: +358 29 522 3341 fax:+358 29 522 3002 e-mail:<a href="mailto:clinicaltrials@fimea.fi">clinicaltrials@fimea.fi</a> website:<a href="http://www.fimea.fi">http://www.fimea.fi</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/finland.jpg" alt="" width="250" height="103"> <td bgcolor="#FFFFFF" class="textBody"> </td> <tr> <td bgcolor="#F3F3F3" class="textBody">France <td bgcolor="#F3F3F3" class="textBody"><a href="http://ansm.sante.fr/" target="_blank">Agence Nationale de S茅curit茅 du M茅dicament et des Produits de Sant茅 </a> <td bgcolor="#F3F3F3" class="textBody">tel: + 331 5587 3000 fax:+ 331 5587 3832 website: <a href="http://ansm.sante.fr/" target="_blank">http://ansm.sante.fr</a> e-mail: <a href="mailto:questions.clinicaltrials@ansm.sante.fr">questions.clinicaltrials@ansm.sante.fr</a> Clinical trial submissions (including end of trial form): <a href="mailto:aec@ansm.sante.fr">aec@ansm.sante.fr</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/france.gif" alt="" width="308" height="107"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Germany (BfArM) <td bgcolor="#FFFFFF" class="textBody"><a href="http://www.bfarm.de/" target="_blank">Federal Institute for Drugs and medical Devices </a> <td bgcolor="#FFFFFF" class="textBody">tel: +49 0 228 207 4318 fax:+49 0 228 207 4355 email:<a href="mailto:ct@bfarm.de">ct@bfarm.de</a> website:<a href="http://www.bfarm.de/" target="_blank">http://www.bfarm.de/</a> Trial submissions (including end of trial form): <a href="https://cespportal.hma.eu/Account/Login?ReturnUrl=%2f" target="_blank">https://cespportal.hma.eu/Account/Login?ReturnUrl=%2f</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/germany2.jpg" alt="" width="196" height="80"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Germany (PEI) <td bgcolor="#F3F3F3" class="textBody"><a href="http://www.pei.de/EN/home/node.html" target="_blank">Paul-Ehrlich Institut</a> <td bgcolor="#F3F3F3" class="textBody">Clinical Trial Section Paul-Ehrlich Str. 55-59 63225 Langen Germany tel: +49 (0)6103 771810 fax:+49 (0) 6103 771277 e-mail:<a href="mailto:ct@pei.de ">ct@pei.de </a> website:<a href="http://www.pei.de/EN/information/license-applicants/clinical-trial-authorisation/clinical-trial-authorisation-node.html " target="_blank">http://www.pei.de/EN/information/license-applicants/clinical-trial-authorisation/clinical-trial-authorisation-node.html </a> Trial submissions (including end of trial): <a href="https://cespportal.hma.eu/Account/Login?ReturnUrl=%2f" target="_blank">https://cespportal.hma.eu/Account/Login?ReturnUrl=%2f</a <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/de2_logo.gif" alt="" width="210" height="48"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Greece <td bgcolor="#FFFFFF" class="textBody"><a href="http://www.eof.gr/" target="_blank">National Organization for Medicines </a> <td bgcolor="#FFFFFF" class="textBody">tel: +302132040376, +302132040355, 302132040327 e-mail: <a href="mailto:trials@eof.gr">trials@eof.gr</a> website: <a href="http://www.eof.gr/" target="_blank">http://www.eof.gr/</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/greece.jpg" alt="" width="426" height="63"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Hungary <td bgcolor="#F3F3F3" class="textBody"><a href="Http://www.ogyei.gov.hu" target="_blank">The National Institute of Pharmacy & Nutrition </a> <td bgcolor="#F3F3F3" class="textBody">tel: +361 8869 311 fax:+361 8869 471 email:<a href="mailto:klinvizsg@nngyk.gov.hu">klinvizsg@nngyk.gov.hu</a> website:<a href="http://www.ogyei.gov.hu" target="_blank"> http://www.ogyei.gov.hu</a> <td class="textBody"><img src="ncalogos/hungary.jpg" alt="" width="84" height="87"> <td class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Iceland <td bgcolor="#FFFFFF" class="textBody"><a href="http://www.ima.is/" target="_blank">Icelandic Medicines Agency </a> <td bgcolor="#FFFFFF" class="textBody">tel: 3545202100 e-mail:<a href="mailto:clinical.trials@ima.is">clinical.trials@ima.is</a> website: <a href="https://www.ima.is/development/clinical-trials/" target="_blank">https://www.ima.is/development/clinical-trials/</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/lyfjastofnun_logo.jpg" alt="" width="270" height="80"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Ireland <td bgcolor="#F3F3F3" class="textBody"><a href="http://www.hpra.ie" target="_blank">Health products Regulatory Authority (HPRA) </a> <td bgcolor="#F3F3F3" class="textBody">Kevin O'Malley House Earlsfort Centre Earlsfort Terrace Dublin 2, Ireland tel: +353 1 6764971 fax:+353 1 6767836 email: <a href="mailto:clinicaltrials@hpra.ie">clinicaltrials@hpra.ie</a> website:<A href="http://www.hpra.ie" target="_blank"> http://www.hpra.ie</A> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/ireland.jpg" alt="" width="344" height="130"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Italy <td bgcolor="#FFFFFF" class="textBody"><a href="http://www.agenziafarmaco.gov.it/" target="_blank">Italian Medicines Agency </a> <td bgcolor="#FFFFFF" class="textBody">tel: +390 659 784357 fax:+390 659 784720 e-mail: <a href="mailto:sperimentazione.clinica@aifa.gov.it">sperimentazione.clinica@aifa.gov.it</a> website: <a href="http://www.agenziafarmaco.gov.it/" target="_blank">http://www.agenziafarmaco.gov.it/</a> clinical trials submissions (including end of trial): <a href="https://www.aifa.gov.it/en/osservatorio-nazionale-sperimentazione-clinica" target="_blank">https://www.aifa.gov.it/en/osservatorio-nazionale-sperimentazione-clinica</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/italy.jpg" alt="" width="119" height="50"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Latvia <td bgcolor="#F3F3F3" class="textBody"><a href="http://www.zva.gov.lv" target="_blank">State Agency of Medicines of the Republic of Latvia</a> <td bgcolor="#F3F3F3" class="textBody">Jersikas street 15, Riga, LV-1003, Latvia tel: +371 67078433 fax:+371 67078428 e-mail: <a href="mailto:CT@zva.gov.lv ">CT@zva.gov.lv </a> website:<a href="http://www.zva.gov.lv" target="_blank"> http://www.zva.gov.lv聽聽</a>聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽聽 <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/latvia.jpg" width="361" height="133" alt="Latvia"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Liechtenstein <td bgcolor="#FFFFFF" class="textBody"><a href="http://www.ag.llv.li" target="_blank">Amt f眉r Gesundheit </a> <td bgcolor="#FFFFFF" class="textBody">脛ulestrasse 51 9490 Vaduz tel: + 00423 236 73 31 (secr) fax:+ 00423 236 73 50 e-mail: <a href="mailto:pharminfo@llv.li">pharminfo@llv.li </a>website:<a href="http://www.ag.llv.li " target="_blank">http://www.ag.llv.li </a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/liechtenstein.jpg" alt="" width="159" height="70"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Lithuania <td bgcolor="#F3F3F3" class="textBody"><a href="http://www.vvkt.lt/">The State Medicines Control Agency </a> <td bgcolor="#F3F3F3" class="textBody">沤irm奴n懦 str. 139A,LT-09120 Vilnius, Lithuania tel: +370 67313235 fax:+370 52639265 e-mail: <a href="mailto:ClinicalTrials@vvkt.lt">ClinicalTrials@vvkt.lt</a> website: <a href="http://www.vvkt.lt/" target="_blank">http://www.vvkt.lt/</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/lithuania.jpg" alt="" width="100" height="106"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Luxembourg <td bgcolor="#FFFFFF" class="textBody"><a href="http://www.ms.public.lu/" target="_blank">Minist猫re de la Sant茅 </a> <td bgcolor="#FFFFFF" class="textBody">Villa Louvigny All茅e Marconi L-2120 Luxembourg tel: +35224785593 fax:+35224795615 e-mail:<a href="mailto:clinicaltrials@ms.etat.lu">clinicaltrials@ms.etat.lu</a> End of trial forms to be sent to: <a href="recherchebiomedicale@ms.etat.lu" target="_blank">recherchebiomedicale@ms.etat.lu</a> website: <a href="http://www.ms.public.lu/" target="_blank">http://www.ms.public.lu/</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/luxembourg.jpg" alt="" width="88" height="80"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Malta <td bgcolor="#F3F3F3" class="textBody"><a href="http://www.medicinesauthority.gov.mt" target="_blank">Medicines Authority </a> <td bgcolor="#F3F3F3" class="textBody">Sir Temi 呕ammit Buildings, Malta Life Sciences Park, San 臓wann, S臓N 3000, Malta website: <A href="http://www.medicinesauthority.gov.mt" target="_blank">http://www.medicinesauthority.gov.mt</A> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/malta.jpg" width="360" height="94" alt=""/> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Netherlands <td bgcolor="#FFFFFF" class="textBody"><a href="http://www.ccmo.nl" target="_blank">CCMO</a> <td bgcolor="#FFFFFF" class="textBody">Parnassusplein 5 2511 VX The Hague tel: +31703406700 NCA email (clinical trials submissions, <a href="https://english.ccmo.nl/investigators/during-and-after-the-research/suspension-or-premature-end-of-study/end-of-study">including EoT form</a>): <a href="mailto:bi@ccmo.nl">bi@ccmo.nl</a> General email:<a href="mailto:ccmo@ccmo.nl"> ccmo@ccmo.nl</a> website: <a href="http://www.ccmo.nl">http://www.ccmo.nl</a> <a href="mailto:ccmo@ccmo.nl"></a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/CCMO-logo.jpg" alt="" width="179" height="65"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Norway <td bgcolor="#F3F3F3" class="textBody"><a href="http://www.legemiddelverket.no/english/Sider/default.aspx" target="_blank">Norwegian medicines Agency </a> <td bgcolor="#F3F3F3"class="textBody">Grensesvingen 26, 0663 Oslo tel: +47 22 89 77 00 e-mail for queries on clinical trials:<a href="mailto:klut@noma.no">klut@noma.no</a> e-mail for submissions:<a href="mailto:post@noma.no">post@noma.no</a><a href="mailto:klut@noma.no"></a> website: <a href="https://www.dmp.no/godkjenning/klinisk-utproving" target="_blank">https://www.dmp.no/godkjenning/klinisk-utproving</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/Norway logo.png" alt="" width="300" height="151"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Poland <td bgcolor="#FFFFFF" class="textBody"><a href="http://en.urpl.gov.pl/general-information" target="_blank">The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products </a> <td bgcolor="#FFFFFF" class="textBody">Address for submissions (including end of trial notifications): Al. Jerozolimskie 181C 02-222 Warszawa tel.: + 48 22 492 11 00 fax: + 48 22 492 11 09 e-mail: <A href="mailto:ndl@urpl.gov.pl">urpl@urpl.gov.pl</A> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/poland.jpg" alt="" width="92" height="94"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Portugal <td bgcolor="#F3F3F3" class="textBody"><a href="http://www.infarmed.pt/portal/page/portal/INFARMED/ENGLISH" target="_blank">Infarmed </a> <td bgcolor="#F3F3F3" class="textBody">Parque de Sa煤de de Lisboa Avenida do Brasil, n潞53. 1749-004 Lisboa Portugal. tel: +351217987283 fax:+351217987248 e-mail: <a href="mailto:ensaios.clinicos@infarmed.pt">ensaios.clinicos@infarmed.pt</a> website: <a href="http://www.infarmed.pt/portal/page/portal/INFARMED/MEDICAMENTOS_USO_HUMANO/ENSAIOS_CLINICOS" target="_blank">Infarmed Clinical Trials page</a> clinical trials submissions: <a href="https://www.rnec.pt/" target="_blank">https://www.rnec.pt/</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/infarmed_logo.png" alt="" width="242" height="80"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Romania <td bgcolor="#FFFFFF" class="textBody"><a href="http://www.anm.ro/anmdm/en/" target="_blank">National Agency for Medicines and Medical Devices </a> <td bgcolor="#FFFFFF" class="textBody">Str. Aviator S膬n膬tescu nr. 48, sector 1 Bucure艧ti 011478- RO tel: + 4 0757 117 259 fax: +4 0213 163 497 website: <a href="http://www.anm.ro/anmdm/ " target="_blank">http://www.anm.ro/anmdm/ </a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/romania.jpg" alt="" width="96" height="70"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Slovakia <td bgcolor="#FFFFFF"class="textBody"><a href="http://www.sukl.sk/" target="_blank">State Institute for Drug Control</a> <td bgcolor="#FFFFFF" class="textBody">Kvetn谩 11 825 08 Bratislava 26 Slovak Republic tel: 004212 5070 1209 fax:004212 5070 1237 e-mail: <a href="mailto:trial-sukl@sukl.sk">trial-sukl@sukl.sk</a> website: <a href="http://www.sukl.sk/ " target="_blank">http://www.sukl.sk/ </a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/sukl_logo.gif" alt="" width="202" height="78"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#F3F3F3"class="textBody">Slovenia <td bgcolor="#F3F3F3"class="textBody"><a href="http://www.jazmp.si/" target="_blank">Agency of the Republic of Slovenia for Medicinal Products and Medical Devices </a> <td bgcolor="#F3F3F3" class="textBody">Sloven膷eva ulica 22, 1000 Ljubljana tel: +38682000544 fax:+38682000510 e-mail: <a href="mailto:ct@jazmp.si">ct@jazmp.si</a> website:<a href="mailto:luxdpm@ms.etat.lu">http://www.jazmp.si/</a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/slovenia.jpg" width="229" height="71" alt=""/> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td bgcolor="#FFFFFF" class="textBody">Spain <td bgcolor="#FFFFFF" class="textBody"><a href="http://www.aemps.gob.es/">AEMPS </a> <td bgcolor="#FFFFFF" class="textBody">tel: +34 902 101322/+34 91 822 59 97 fax:+34 918 225076 e-mail: <a href="mailto:aecaem@aemps.es">aecaem@aemps.es</a> website: EMC website, for submissions, including end of trial form: <a href="https://ecm.aemps.es/ecm/informacionGeneral.do">https://ecm.aemps.es/ecm/informacionGeneral.do</a></td> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/spain.jpg" alt="" width="165" height="56"> <td bgcolor="#FFFFFF"class="textBody"> <tr> <td bgcolor="#F3F3F3" class="textBody">Sweden <td bgcolor="#F3F3F3"class="textBody"><a href="https://lakemedelsverket.se/english/" target="_blank">Medical Products Agency </a> <td bgcolor="#F3F3F3" class="textBody">tel:+ 461 8174600 fax:+461 8548566 e-mail: <a href="mailto:registrator@lakemedelsverket.se">registrator@lakemedelsverket.se </a> <td bgcolor="#FFFFFF" class="textBody"><img src="ncalogos/sweden.jpg" alt="" width="217" height="33"> <td bgcolor="#FFFFFF" class="textBody"> <td bgcolor="#FFFFFF" class="textBody"> <tr> <td colspan="5" class="textBody"><table> <tr> <td style="vertical-align:top; padding-right:15px;"><img src="images/logo_emea.jpg" width="300" height="57" alt="EMA"></td> <td class="footer">Last Updated: January 30, 2024 12:00 European Medicines Agency 漏 1995-2024 </td> </tr> </table></td> </tr> </table> </body> </html> <script id="f5_cspm">(function(){var f5_cspm={f5_p:'DMNJHNCPKLBPEBBMHBLFBHBNKMCMPIDFLPKDFBKPJHGIFOPEINJMKNKDOAIMFOCIPMEBJCBPAABFJEBMBOFAGPCAAAKJCLPPBDKLAOGJOGBDEAJHCJHBHDMMIGKOFNMN',setCharAt:function(str,index,chr){if(index>str.length-1)return str;return str.substr(0,index)+chr+str.substr(index+1);},get_byte:function(str,i){var s=(i/16)|0;i=(i&15);s=s*32;return((str.charCodeAt(i+16+s)-65)<<4)|(str.charCodeAt(i+s)-65);},set_byte:function(str,i,b){var s=(i/16)|0;i=(i&15);s=s*32;str=f5_cspm.setCharAt(str,(i+16+s),String.fromCharCode((b>>4)+65));str=f5_cspm.setCharAt(str,(i+s),String.fromCharCode((b&15)+65));return str;},set_latency:function(str,latency){latency=latency&0xffff;str=f5_cspm.set_byte(str,40,(latency>>8));str=f5_cspm.set_byte(str,41,(latency&0xff));str=f5_cspm.set_byte(str,35,2);return str;},wait_perf_data:function(){try{var wp=window.performance.timing;if(wp.loadEventEnd>0){var res=wp.loadEventEnd-wp.navigationStart;if(res<60001){var cookie_val=f5_cspm.set_latency(f5_cspm.f5_p,res);window.document.cookie='f5avr1377058531aaaaaaaaaaaaaaaa_cspm_='+encodeURIComponent(cookie_val)+';path=/;'+'';} return;}} catch(err){return;} setTimeout(f5_cspm.wait_perf_data,100);return;},go:function(){var chunk=window.document.cookie.split(/\s*;\s*/);for(var i=0;i<chunk.length;++i){var pair=chunk[i].split(/\s*=\s*/);if(pair[0]=='f5_cspm'&&pair[1]=='1234') {var d=new Date();d.setTime(d.getTime()-1000);window.document.cookie='f5_cspm=;expires='+d.toUTCString()+';path=/;'+';';setTimeout(f5_cspm.wait_perf_data,100);}}}} f5_cspm.go();}());</script>

CINXE.COM

EudraCT Public website -NCAs page